



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/073,365	02/13/2002	Yeckezkel Barenholz	BARENHOLTZ=1A	5480

1444 7590 05/19/2005

BROWDY AND NEIMARK, P.L.L.C.
624 NINTH STREET, NW
SUITE 300
WASHINGTON, DC 20001-5303

EXAMINER

KISHORE, GOLLAMUDI S

ART UNIT PAPER NUMBER

1615

DATE MAILED: 05/19/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

10/073,365

Applicant(s)

BARENHOLZ ET AL.

Examiner

Gollamudi S. Kishore, Ph.D

Art Unit

1615

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 25 February 2005.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 50-55, 58-83 and 88-92 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 50-55, 58-83 and 88-92 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

RD

DETAILED ACTION

The amendment dated 2-25-05 is acknowledged.

Claims included in the prosecution are 51-55, 58-83 and 88-92.

Claim Rejections - 35 USC § 112

1. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

2. Claim 55 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 55 depends from the canceled claim 50. However, this claim is included in the prosecution as dependent from the newly added independent claim 90 with the assumption that it is a typographical error and

Claim Rejections - 35 USC ' 103

1. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

2. Claims 51-55, 58-83 and 88-92 are rejected under 35 U.S.C. 103(a) as being unpatentable over Stahl (FEBS Letters, 427, 1998).

As pointed out above, Stahl discloses liposomal formulations containing carotenoid, lycopene (note the abstract, Materials and Methods and Tables). According to Stahl, the antioxidant activity of lycopene is greater than other anti-oxidants, alpha-tocopherol, alpha-carotene, beta-cryptoxanthin, Zeaxanthin, beta-carotene and lutein (abstract).

According to the method as disclosed in section 2.3 on page 305, carotenoids, alpha tocopherol or mixtures are dissolved together with phosphatidylcholine in chloroform, the solvent is evaporated and the multilamellar vesicles are prepared by the addition of phosphate buffer followed by sonication. This implies that the carotenoid is added chloroform, which has already dissolved phospholipid. In Stahl, the solvent is removed under Nitrogen and not lyophilized. In the absence of showing the criticality, this step is a manipulatable step since lyophilization is a commonly used process in liposome technology. It is unclear from Stahl as to how much phospholipid was used; however, in the absence of showing the criticality, it is deemed obvious to one of ordinary skill in the art to manipulate the amounts of the phospholipid since the phospholipid amounts determine how many liposomes are formed and how much of the lipophilic carotenoids are incorporated in the lipid bilayers. Stahl does not teach cyclohexane as the organic solvent. However, the purpose the solvent is to dissolve the phospholipid, it is deemed obvious to one of ordinary skill in the art to select a suitable solvent as long as it serves the desired purpose. The criticality of phosphatidylcholine

obtained from different sources or cyclohexane is not readily apparent to the examiner in the absence of comparative studies. Stahl does not teach a kit. However, it is deemed obvious to one of ordinary skill in the art to supply the components in the form of a kit so that the artisan can obtain fresh preparations of liposomes when needed. Stahl does not teach that the compositions in a pharmaceutically or cosmetically suited form and that the composition is for the prevention of the damage caused by free radicals. However, since Stahl's studies show that lycopene has greater anti-oxidant activity than other carotenoids, it is deemed obvious to one of ordinary skill in the art to prepare the compositions in a suitable form for the administration and prevention of damage caused by the free radicals.

Applicant's arguments have been fully considered, but are not found to be persuasive. Applicant argues that the claims have been amended to recite that the liposomes be prepared by freeze-drying step and this step unexpectedly produces superior liposomes compared to the liposomes prepared by conventional methods. This statement by applicant is based on the experimental data obtained using lycopene (declaration). Apparently applicant's interpretation of the results is based on the amount of lycopene not decomposed by the process. Applicant's arguments are not persuasive since the data in the declaration is not commensurate with the scope of the claims in terms of the solvent used and the generic carotenoid. Lyophilization is a process, which involves freezing of the solution and then subjecting the frozen preparation to vacuum. Solutions containing organic solvents do not in general freeze at the freezing temperature used in the lyophilization process and applicant has not shown that this

Art Unit: 1615

method can be used for all the organic solvents. Secondly, lycopene is a unique carotenoid which has open ring structure unlike beta-carotene or alpha carotene (both beta ionone rings are open in lycopene) and applicant has not shown unexpected results with other carotenoids.

9. Claims 51-55, 58-83 and 88-92 are rejected under 35 U.S.C. 103(a) as being unpatentable over Meybeck in view of Stahl cited above.

The teachings of Meybeck have been discussed before. In essence, Meybeck discloses topical liposomal formulations containing a carotenoid (beta-carotene) for dermatological and cosmetic applications. The applications include, 'fighting aging' and 'protection against sun' (protection against free-radicals, singlet oxygen). The compositions can also be administered orally (abstract, col. 3, lines 19-46; Examples 1 and 17, and claims). The method of preparation of liposomes disclosed by Meybeck is similar to instant method. The method involves dissolving the phospholipid and the carotenoid in an organic solvent and removing the solvent to prepare a dry preparation (as opposed to instant steps where the lipid is first dissolved in the organic solvent and then carotenoid is added to this solution), hydrating the powder with an aqueous medium and lyophilizing the liposomes and hydrating them again when needed. Although there is no explicit teaching in Meybeck that the liposome forming lipids in the organic solvent is to a level close to saturation, as pointed out above, the amounts of the phospholipid used by Meybeck as seen from examples are more than the amounts

noted in instant specification. Assuming that they are different, it is deemed obvious to one of ordinary skill in the art to manipulate the amounts of the phospholipid since the phospholipid amounts determine how many liposomes are formed and how much of the lipophilic carotenoids are incorporated in the lipid bilayers. Meybeck does not teach cyclohexane as the organic solvent. However, the purpose the solvent is to dissolve the phospholipid, it is deemed obvious to one of ordinary skill in the art to select a suitable solvent as long as it serves the desired purpose. In Meybeck, the solvent is not removed by lyophilization process. However, it is deemed obvious to one of ordinary skill in the art to use this process since it is commonly used in liposome technology. Meybeck does not teach a kit. However, it is deemed obvious to one of ordinary skill in the art to supply the components in the form of a kit so that the artisan can obtain fresh preparations of liposomes when needed.

What is also lacking in Meybeck is the teaching that the carotenoid be lycopene. What is also lacking in Meybeck is the method wherein the phospholipid is dissolved in the solvent first followed by the carotenoid.

As pointed out above, Stahl discloses liposomal formulations containing carotenoid, lycopene (note the abstract, Materials and Methods and Tables). According to Stahl, the antioxidant activity of lycopene is greater than other anti-oxidants, alpha-tocopherol, alpha-carotene, beta-cryptoxanthin, Zeaxanthin, beta-carotene and lutein (abstract). According to the method as disclosed in section 2.3 on page 305, carotenoids, alpha tocopherol or mixtures are dissolved together with phosphatidylcholine in chloroform, the solvent is evaporated and the multilamellar

vesicles are prepared by the addition of phosphate buffer followed by sonication. This implies that the carotenoid is added chloroform, which has already dissolved phospholipid.

It is unclear from Smith as to how much phospholipid was used; however, in the absence of showing the criticality, it is deemed obvious to one of ordinary skill in the art to manipulate the amounts of the phospholipid since the phospholipid amounts determine how many liposomes are formed and how much of the lipophilic carotenoids are incorporated in the lipid bilayers. Stahl does not teach cyclohexane as the organic solvent. However, the purpose the solvent is to dissolve the phospholipid, it is deemed obvious to one of ordinary skill in the art to select a suitable solvent as long as it serves the desired purpose. Stahl does not teach a kit. However, it is deemed obvious to one of ordinary skill in the art to supply the components in the form of a kit so that the artisan can obtain fresh preparations of liposomes when needed.

It would have been obvious to one of ordinary skill in the art to use lycopene as the as the carotenoid in Meybeck's liposomal formulations since Stahl teaches that the antioxidant activity of lycopene is greater than other anti-oxidants, alpha-tocopherol, alpha-carotene, beta-cryptoxanthin, Zeaxanthin, beta-carotene and lutein.

Applicant's arguments have been fully considered, but are not found to be persuasive. Applicant's arguments with regard to lyophilization process have been addressed above. Applicant argues that the order of adding the components is important. However, applicant adds an independent claim expanding the scope of the claims to 'carotenoids' and as pointed out above, lycopene is different from other

Art Unit: 1615

carotenoids in having an open ring structure and applicant has not shown the criticality of this step with carotenoids other than lycopene.

10. Claims 51-55, 58-83 and 88-92 are rejected under 35 U.S.C. 103(a) as being unpatentable over WO 94/13265 (Smith) of record in view of Stahl cited above.

WO discloses liposomal formulations containing beta-carotene for prevention of oxidation damage caused by singlet oxygen and other reactive oxygen species. The liposomes are made from phospholipids including egg phosphatidylcholine. The mode of administration is either topical or oral (capsules or tablets) (abstract, pages 4-6, 9-11, Examples and claims). The method of preparation involves for example dissolving 20 mg of the phospholipid in 2 ml of solvent system together with amphiphilic antioxidants, evaporating to dryness and hydrating the lipid mixture. This implies that the phospholipid is added first to the solvent. In WO, the solvent is not removed by lyophilization process. However, it is deemed obvious to one of ordinary skill in the art to use this process since it is commonly used in liposome technology. What is lacking in WO is the teaching of the carotenoid, lycopene.

As pointed out above, Stahl discloses liposomal formulations containing carotenoid, lycopene (note the abstract, Materials and Methods and Tables). According to Stahl, the antioxidant activity of lycopene is greater than other anti-oxidants, alpha-tocopherol, alpha-carotene, beta-cryptoxanthin, Zeaxanthin, beta-carotene and lutein (abstract).

It would have been obvious to one of ordinary skill in the art to use lycopene as the as the carotenoid in Meybeck's liposomal formulations since Stahl teaches that the antioxidant activity of lycopene is greater than other anti-oxidants, alpha-tocopherol, alpha-carotene, beta-cryptoxanthin, Zeaxanthin, beta-carotene and lutein.

11. Claim 55 is rejected under 35 U.S.C. 103(a) as being unpatentable over Meybeck, or Stahl cited above, further in view of Mackaness (4,192,859).

The teachings of Meybeck and Stahl have been discussed above. What is lacking in Meybeck or Stahl is the use of cyclohexane as the solvent in the preparation of liposomes.

The use of cyclohexane would have been obvious to one of ordinary skill in the art, with the expectation of obtain at least similar results, since Mackaness teaches that organic solvents such as cyclohexane and chloroform could be used in dissolving the phospholipids in the preparation of liposomes (col. 3, lines 40-45).

Applicant's arguments have been fully considered, but are not found to be persuasive. Applicant argues that even though Mackaness discloses hexane (cyclohexane) as the solvent to dissolve phospholipids, he does not supply any suggestion or disclosure to add the phospholipid to the solvent prior to adding the carotenoid or lyophilization. These arguments have not been found to be persuasive since applicant has not shown the criticality of these steps with carotenoids other than lycopene.

The reference of Frederiksen (5,700,482), which shows lyophilization for solvent removal, is cited of interest.


Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gollamudi S Kishore, Ph.D whose telephone number is (571) 272-0598. The examiner can normally be reached on 6:30 AM- 4 PM, alternate Friday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman K Page can be reached on (571) 272-0602. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).


Gollamudi S Kishore, Ph.D
Primary Examiner
Art Unit 1615

GSK